LL-37: Community Protocols & Reports
Aggregated community experiences, protocols, and stacking patterns
Community-Sourced Information
The protocols and reports on this page are gathered from online communities and forums. They represent anecdotal experiences, not clinical evidence. Individual results vary significantly. This information is not medical advice and should not replace consultation with a qualified healthcare provider. Always verify dosing and safety information with peer-reviewed research before making any decisions.
For peer-reviewed dosing protocols, see the clinical dosing guide.
Browse community protocols for all 130 peptides โ
๐TL;DR
- โข4 community protocols documented
- โขEvidence level: Anecdotal Reports
- โขBased on 45 community reports
- โข3 stacking patterns reported
Clinical vs. Community Protocol Differences
How community-reported protocols differ from clinical research protocols.
| Aspect | Clinical Approach | Community Approach | Significance |
|---|---|---|---|
| Administration Route | Published research on LL-37 is predominantly in vitro or uses topical application in wound healing studies. No established systemic injection protocol exists in clinical literature. | Community exclusively uses subcutaneous injection for systemic immune effects. Some practitioners also use it in nebulized form for respiratory infections. | high The subcutaneous injection route for LL-37 is entirely community-derived. The pharmacokinetics, distribution, and safety of systemically injected LL-37 in humans are not well characterized. |
| Dosing | In vitro studies use concentrations typically in the 1-50 micromolar range. Topical wound studies use varying concentrations. No standardized systemic dose has been established in human trials. | Community uses fixed doses of 100-400 mcg subcutaneously. Gradual titration from 50 mcg is recommended by experienced users to assess tolerance. | high Community doses are derived from practitioner experience and anecdotal dose-finding rather than formal pharmacokinetic studies. |
| Indication | Research focuses on antimicrobial properties, wound healing, and innate immune modulation in preclinical models. | Community uses LL-37 for general immune support, chronic infections, Lyme disease, gut issues, and biofilm disruption. | moderate Community indications extend beyond preclinical research focus areas. Biofilm disruption claims are based on in vitro data. |
Compare these community approaches with published research findings.
Community Protocols
Standard Immune Protocol
Popular- Route
- Subcutaneous
- Dose
- 100-200 mcg
- Frequency
- Once daily (5 days on, 2 days off)
- Duration
- 8-12 weeks
Most commonly reported protocol; gradual titration from 50 mcg recommended
Acute Infection Protocol
Common- Route
- Subcutaneous
- Dose
- 200-400 mcg
- Frequency
- Once daily
- Duration
- 2-4 weeks
Higher dose used during active infections; some users report flu-like symptoms at higher doses
Gut Repair Protocol
Common- Route
- Subcutaneous
- Dose
- 100 mcg
- Frequency
- Once daily
- Duration
- 4-8 weeks
Lower dose used for gut-related issues; often stacked with BPC-157 for gut healing
Slow Titration Protocol
Niche- Route
- Subcutaneous
- Dose
- 50-400 mcg (gradual increase)
- Frequency
- Once daily
- Duration
- 8-16 weeks
Start at 50 mcg, increase by 50 mcg weekly as tolerated; targeting 200-400 mcg daily by weeks 4-8
Stacking Patterns
Immune Defense Stack
CommonCombined innate (LL-37) and adaptive (TA1) immune stimulation for comprehensive immune support
Gut Healing + Immune Stack
CommonLL-37 for antimicrobial and immune modulation with BPC-157 for gut mucosal healing; popular for SIBO and dysbiosis concerns
Check stack compatibility and review potential side effects before combining peptides.
Unlock community dosing protocols and stacking combos
See the exact doses, routes, and schedules 45+ self-experimenters report. Free with email.
150+ peptide profiles ยท 30+ comparisons ยท 18 research tools
Sources
- Reddit r/Peptides|LL-37 experience reports and immune protocol discussions(accessed 2026-02-16)
- Swolverine|LL-37 For Beginners: Healing, Immunity, and Dosing Guide(accessed 2026-02-16)
- Peptides.org|LL-37 Dosage Calculator and Chart(accessed 2026-02-16)
- PeptideDosages.com|LL-37 5mg Vial Dosage Protocol and Reconstitution Guide(accessed 2026-02-16)
- Peptide Dojo|LL-37 Dosing Guide: Complete Research Protocol(accessed 2026-02-16)
Community Evidence Overview#
This page presents aggregated community protocols and anecdotal reports for LL-37 (cathelicidin). The information below is gathered from peptide research forums, Reddit communities, and self-experimenter reports. This is not clinical evidence and should not be used as medical guidance.
LL-37 has gained significant community interest as an antimicrobial and immune-modulating peptide. As the only human cathelicidin, it has extensive preclinical research backing its antimicrobial and immune-modulating properties, though no formal human clinical trials for systemic injection exist.
Understanding Protocol Divergence#
Route of Administration#
The most critical divergence for LL-37 is the administration route. Published research is predominantly in vitro (cell culture) or uses topical application for wound healing. The community has adopted subcutaneous injection as the primary route, which is entirely community-derived. The pharmacokinetics of systemically injected LL-37 are not well characterized in humans.
Dose Selection#
Community dosing of 100-400 mcg is based on practitioner experience and anecdotal dose-finding rather than formal pharmacokinetic studies. The gradual titration approach (starting at 50 mcg and increasing weekly) reflects the community's awareness that immune activation can produce uncomfortable side effects.
Commonly Reported Outcomes#
Community members frequently report the following when using LL-37:
- Immune activation symptoms: Low-grade fever, fatigue, and body aches in the first few days, interpreted as immune system engagement
- Reduced infection frequency: Users report fewer respiratory infections over time
- Gut health improvements: Some users report reduced bloating and improved digestion when combined with BPC-157
- Skin improvements: Occasional reports of improved wound healing and reduced skin infections
Important Caveats#
- LL-37 has no established human clinical dosing for systemic injection
- Immune activation side effects may be difficult to distinguish from illness
- Individuals with autoimmune conditions should exercise particular caution as LL-37 may aggravate symptoms
- Product quality and purity are critical for an antimicrobial peptide
Reconstitution and Storage Practices#
- Reconstitution: 1-2 mL bacteriostatic water per 5 mg vial
- Storage: Reconstituted solution refrigerated at 2-8 degrees C
- Shelf life: Most users report using reconstituted LL-37 within 2-3 weeks
- Injection volume: Typically 0.1-0.3 mL per injection depending on concentration
Related Reading#
Subscribe to see vendor options
Free access to verified vendor scores, pricing, and suppliers.
150+ peptide profiles ยท 30+ comparisons ยท 18 research tools
Frequently Asked Questions About LL-37
Explore Further
Medical Disclaimer
This website is for educational and informational purposes only. The information provided is not intended to diagnose, treat, cure, or prevent any disease. Always consult with a qualified healthcare professional before using any peptide or supplement.